We are live on ! Find out more
BG

Bahl & Gaynor Portfolio holdings

AUM $19.8B
1-Year Est. Return 19.53%
This Fund
S&P 500
This Quarter Est. Return
+5.56%
1 Year Est. Return
+19.53%
3 Year Est. Return
+63.97%
5 Year Est. Return
+84.2%
10 Year Est. Return
+296.44%
AUM
$14.4B
AUM Growth
+$580M
Cap. Flow
-$102M
Cap. Flow %
-0.7%
Top 10 Hldgs %
30.89%
Holding
368
New
16
Increased
155
Reduced
158
Closed
9

Top Buys

Rank Stock Value
1
ADP icon
Automatic Data Processing
ADP
+$64.6M
2
LLY icon
Eli Lilly
LLY
+$31.3M
3
MDLZ icon
Mondelez International
MDLZ
+$25.7M
4
AVGO icon
Broadcom
AVGO
+$21.7M
5
PSX icon
Phillips 66
PSX
+$11.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$45.1M
2
HPQ icon
HP
HPQ
+$40M
3
NEE icon
NextEra Energy
NEE
+$33M
4
PAYX icon
Paychex
PAYX
+$25.1M
5
CSCO icon
Cisco
CSCO
+$19.9M

Sector Composition

Rank Sector Weight
1 Technology 19.25%
2 Financials 16.25%
3 Healthcare 12.13%
4 Consumer Staples 10.11%
5 Industrials 9.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ZBRA icon
351
Zebra Technologies
ZBRA
$17.8B
$204K ﹤0.01%
+800
New +$187K
ET icon
352
Energy Transfer Partners
ET
$69.3B
$201K ﹤0.01%
15,680
LYTS icon
353
LSI Industries
LYTS
$924M
$165K ﹤0.01%
27,215
NOK icon
354
Nokia
NOK
$52.3B
$81K ﹤0.01%
21,900
ALB icon
355
Albemarle
ALB
$15.5B
-13,192
Closed -$917K
AOS icon
356
A.O. Smith
AOS
$8.7B
-26,274
Closed -$1.25M
BCE icon
357
BCE
BCE
$21.2B
-4,252
Closed -$206K
KLAC icon
358
KLA
KLAC
$259B
-199,680
Closed -$3.18M
PAHC icon
359
Phibro Animal Health
PAHC
$1.39B
-45,980
Closed -$980K
PDCO
360
DELISTED
Patterson Companies, Inc.
PDCO
-107,686
Closed -$1.92M
VYNT
361
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
-133
Closed -$2K
CY
362
DELISTED
Cypress Semiconductor
CY
-56,537
Closed -$1.32M

Similar funds

Bahl & Gaynor's Q4 2019 Portfolio in Review

As of Q4 2019, Bahl & Gaynor held 368 positions worth $14.4B, up 4.2% from $13.8B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Bahl & Gaynor's Q4 2019 filing shows 16 new, 155 increased, 158 reduced and 9 closed positions. Its largest new stake was Penske Automotive Group: 54,533 shares worth $2.74M. The largest sale was Pfizer, an estimated $45.1M.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.

  • Bahl & Gaynor's largest Q4 2019 buy was Penske Automotive Group: 54,533 shares worth $2.74M.
  • Bahl & Gaynor added most to Automatic Data Processing in Q4 2019, an estimated $64.6M increase.
  • Bahl & Gaynor's biggest Q4 2019 reduction was Pfizer, cutting an estimated $45.1M.
  • Bahl & Gaynor fully exited KLA in Q4 2019, selling an estimated $3.18M.
  • Bahl & Gaynor's ten largest holdings make up 31% of its $14.4B portfolio in Q4 2019.
  • Bahl & Gaynor opened 16 new positions and closed 9 in Q4 2019.
  • Bahl & Gaynor's portfolio value rose 4.2% quarter-over-quarter to $14.4B.

Based on Bahl & Gaynor's 13F filing for Q4 2019, filed 14 Feb 2020.